Obese mice treated with MOTS-C peptide gain less weight and exhibit better glucose tolerance versus controls
It also can lead to swelling or, in extreme cases, thermal runaway 6
We found no significant difference among studied administrated routes in all other CBC parameters such as Hb, MCV, platelets count, WBC count, and homocysteine level
The generic formulation makes it one of the least expensive branded-mechanism anti-obesity drugs available
obesity trial: cardiometabolic markers, liver fat reduction, lipid profiles Hepatology (2024) Triple agonists in NAFLD/NASH: hepatic steatosis resolution (preclinical and clinical evidence) The Lancet (2023) Supplementary Data Rosenstock et al
[19] Jastreboff, A.M., Kaplan, L.M., Frias, J.P., et al